Harpreet Singh-Jasuja
Founder presso IMMATICS N.V.
Patrimonio netto: 13 M $ in data 31/03/2024
Provenienza dei contatti di primo grado di Harpreet Singh-Jasuja
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Biotechnology | 26 | |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.
22
| Subsidiary | Pharmaceuticals: Major | 22 |
Immatics US, Inc.
 Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.
16
| Subsidiary | Biotechnology | 16 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Harpreet Singh-Jasuja tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| BAYER AG | Pharmaceuticals: Major | General Counsel Corporate Officer/Principal | |
| 2INVEST AG | Financial Conglomerates | Director/Board Member Director/Board Member | |
| Bayer Pharmaceuticals Corp. | Corporate Officer/Principal | ||
| AC IMMUNE SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Biotechnology | Director/Board Member Founder Director/Board Member Director/Board Member | |
| MALLINCKRODT PLC | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | General Counsel Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| MORPHOSYS AG | Biotechnology | Corporate Officer/Principal | |
Franz Haniel & Cie. GmbH
 Franz Haniel & Cie. GmbH Investment ManagersFinance Franz Haniel & Cie. GmbH is a Haniel family equity firm. The company was founded in 1756 by Jan Willem Noot and is headquartered in Duisburg, Germany. | Investment Managers | Director/Board Member | |
Wellington Partners GmbH
 Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| HEIDELBERG PHARMA AG | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
| Eberhard Karls Universität Tübingen | College/University | Undergraduate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| Ruprecht-Karls-Universität Heidelberg | College/University | Undergraduate Degree Director/Board Member Doctorate Degree | |
| University of Regensburg | College/University | Undergraduate Degree | |
| SYMETIS SA | Biotechnology | Director/Board Member Director/Board Member | |
| Ludwig-Maximilians-Universität München | College/University | Doctorate Degree Doctorate Degree | |
American Society of Hematology
 American Society of Hematology Miscellaneous Commercial ServicesCommercial Services American Society of Hematology provides the most current practice tools, clinical support and educational products needed in hematology. The firm offers educational products and services for clinicians and scientists. The company is headquartered in Washington, DC. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Apogenix AG
 Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Biotechnology | Chairman Director/Board Member | |
dievini Hopp BioTech holding GmbH & Co. KG
 dievini Hopp BioTech holding GmbH & Co. KG Investment ManagersFinance dievini Hopp BioTech holding GmbH & Co. KG operates as a private investment and consulting firm. It invests in companies related to the life and health sciences. It focuses with companies that diagnoses and provides therapy in the fields of oncology, neurology, infectious diseases, cell therapy and drug delivery systems. The company is headquartered in Walldorf, Germany. | Investment Managers | Private Equity Investor Founder Chief Executive Officer | |
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| Febit, Inc. | Director/Board Member Chairman | ||
Glycotope GmbH
 Glycotope GmbH BiotechnologyHealth Technology Glycotope GmbH operates as a biotechnology company to develop pharmaceutical therapeutics and nutrition additives. It focuses on the optimization and humanization of therapeutically relevant sugar structures on biopharmaceuticals known as glycosylation and on the development of innovative antibodies targeting glycostructures on cell surfaces. The company was founded by Steffen Goletz and Andreas Eckert in Febraury 2001 and is headquartered in Berlin, Germany. | Biotechnology | Chief Executive Officer | |
| ADVANCED ACCELERATOR APPLICATION SA(ADR) | Medical Specialties | Investor Relations Contact General Counsel | |
| dievini Verwaltungs GmbH | Chief Executive Officer Chief Executive Officer Chief Executive Officer | ||
| JUPEC Verlags GmbH | President | ||
| RITTERSHAUS Steuerberatungsgesellschaft mbH | Chief Executive Officer | ||
| Bohlini GmbH & Co. KG | President | ||
| Bohlini Verwaltungs GmbH | President | ||
Molecular Health GmbH
 Molecular Health GmbH Miscellaneous Commercial ServicesCommercial Services Part of Posbelduf Biotech AG, Molecular Health GmbH is a German management consulting company. The private company is based in Heidelberg, Germany. The company was founded in 2004 by Friedrich von Bohlen und Halbach. Friedrich von Bohlen und Halbach has been the CEO since 2004. | Miscellaneous Commercial Services | Chief Executive Officer Chairman Director/Board Member | |
Molecular Health, Inc.
 Molecular Health, Inc. Packaged SoftwareTechnology Services Molecular Health, Inc. operates as a cloud-based healthcare decision support technology to enable evidence-based treatment decisions. The company was founded in 2004 and is headquartered in Boston, MA. | Packaged Software | Chairman Director/Board Member Director/Board Member | |
Novaliq GmbH
 Novaliq GmbH Medical SpecialtiesHealth Technology Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany. | Medical Specialties | Chairman Director/Board Member | |
| Max Planck Institute of Neurobiology | College/University | Doctorate Degree | |
iOmx Therapeutics AG
 iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Biotechnology | Director/Board Member Director/Board Member | |
| INFLARX N.V. | Biotechnology | Director of Finance/CFO Corporate Officer/Principal | |
Valo Therapeutics Oy
 Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | Pharmaceuticals: Major | Chief Executive Officer | |
| Valo Therapeutics Ltd. | Chief Executive Officer | ||
| CUREVAC N.V. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| IMMUNOCORE HOLDINGS PLC | Biotechnology | Chief Executive Officer Director/Board Member | |
febit holding GmbH
 febit holding GmbH Medical/Nursing ServicesHealth Services febit holding GmbH engages in the design and development of technologies used for DNA analysis. It specializes in technologies with applications in genomic research, RNA expression profiling, and other diagnostic and molecular biology fields. The company was founded by Markus Beier, Ramon Gueimil, Peer F. Staehler, Matthias Scheffler, and Cord F. Stähler in 2005 and is headquartered in Heidelberg, Germany. | Medical/Nursing Services | Director/Board Member Chairman | |
SRH Holding (SdbR)
 SRH Holding (SdbR) Other Consumer ServicesConsumer Services SRH Holding engages in the provision of educational and health care services. It operates universities, vocational schools, vocational rehabilitation centers, acute care hospitals, rehabilitation clinics, and outpatient care centers. The company was founded in 1966 and is headquartered in Heidelberg, Germany. | Other Consumer Services | Chief Executive Officer |
Statistiche
Distribuzione geografica
| Germania | 35 |
| Stati Uniti | 7 |
| Regno Unito | 5 |
| Svizzera | 3 |
| Irlanda | 2 |
Settori
| Health Technology | 25 |
| Consumer Services | 7 |
| Finance | 6 |
| Commercial Services | 6 |
| Technology Services | 2 |
Posizioni
| Director/Board Member | 169 |
| Corporate Officer/Principal | 73 |
| Chairman | 58 |
| Chief Executive Officer | 53 |
| Independent Dir/Board Member | 34 |
Contatti più connessi
| Insiders | |
|---|---|
| Christof Hettich | 40 |
| Friedrich von Bohlen und Halbach | 36 |
| Eliot Forster | 35 |
| Peter Chambré | 23 |
| Katina Dorton | 22 |
| Mathias Hothum | 19 |
| Adam Stone | 17 |
| Harald F. Stock | 17 |
| Michael Atieh | 16 |
| Carsten Reinhardt | 16 |
| Arnd Christ | 15 |
| Erich Schlick | 15 |
| Matthias Kromayer | 14 |
| Heather Mason | 13 |
| Paul Carter | 12 |
- Borsa valori
- Insiders
- Harpreet Singh-Jasuja
- Connessioni Società
